Actinomycin D Arrests Cell Cycle of Hepatocellular Carcinoma Cell Lines and Induces p53-Dependent Cell Death: A Study of the Molecular Mechanism Involved in the Protective Effect of IRS-4

• Main Authors: Luis G. Guijarro (Author), Patricia Sanmartin-Salinas (Author), Eva Pérez-Cuevas (Author), M. Val Toledo-Lobo (Author), Jorge Monserrat (Author), Sofia Zoullas (Author), Miguel A. Sáez (Author), Miguel Angel Álvarez-Mon (Author), Julia Bujan (Author), Fernando Noguerales-Fraguas (Author), Eduardo Arilla-Ferreiro (Author), Melchor Álvarez-Mon (Author), Miguel A. Ortega (Author)
• Format: Book
• Published: MDPI AG, 2021-08-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Actinomycin D (ActD) is an FDA-approved NCI oncology drug that specifically targets and downregulates stem cell transcription factors, which leads to a depletion of stem cells within the tumor bulk. Recently, our research group demonstrated the importance of IRS-4 in the development of liver cancer....